{"id":"tocilizumab-prefilled-syringe-actemra","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Increased risk of malignancies"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interleukin-6 is a cytokine that plays a key role in the inflammatory response. By blocking the interleukin-6 receptor, tocilizumab reduces inflammation and prevents tissue damage. This mechanism of action is particularly useful in treating autoimmune diseases and inflammatory conditions.","oneSentence":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:13.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic sclerosis"},{"name":"Cryopyrin-associated periodic syndromes"},{"name":"Carvajal syndrome"},{"name":"Eosinophilic granulomatosis with polyangiitis"},{"name":"COVID-19"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actemra"],"phase":"phase_3","status":"active","brandName":"Tocilizumab Prefilled Syringe [Actemra]","genericName":"Tocilizumab Prefilled Syringe [Actemra]","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}